Dendritic cell therapy of cancer: Can it fulfill its promise?

Expert Review of Anticancer Therapy

Volumn 3, Issue 1, 2003, Pages 1-3

  Vermorken, Jan B ^a   Van Tendeloo, Viggo F I ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CD8 ANTIGEN; TUMOR REJECTION ANTIGEN;

ADVANCED CANCER; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; CANCER; CANCER IMMUNIZATION; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CLINICAL TRIAL; DENDRITIC CELL; DNA MODIFICATION; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; GENE TRANSFER; HUMAN; HUMORAL IMMUNITY; KILLER CELL; MOLECULAR RECOGNITION; NONHUMAN; PROSTATE CANCER; T LYMPHOCYTE; TREATMENT OUTCOME;

EID: 0037320831     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.3.1.1     Document Type: Editorial

References (13)

1. Berd D. Cancer vaccines: reborn or just recycled? Semin. Oncol. 25, 605-610 (1998).
2. Willimsky G, Blankenstein T. Interleukin-7/B7.1-encoding adenoviruses induce rejection of transplanted but not nontransplanted tumors. Cancer Res. 60, 685-692 (2000).
3. Van Pel A, Boon T. Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis. Proc. Natl Acad. Sci USA 79, 4718-4722 (1982).
4. Gilboa E. The making of a tumor rejection antigen. Immunity 11, 263-270 (1999).
5. Vermorken JB, Claessen AM, van TH et al. Active specific immunotherapy for Stage II and Stage III human colon cancer: a randomised trial. Lancet 353, 345-350 (1999).
6. Pardoll DM. Cancer vaccines. Nature Med. 4, 525-531 (1998).
7. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 392, 245-252 (1998).
8. Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J. Exp. Med. 137, 1142-1162 (1973).
9. Timmerman JM, Levy R. Dendritic cell vaccines for cancer immunotherapy. Ann. Rev. Med. 50, 507-529 (1999).
10. Van Tendeloo VFI, Van Broeckhoven C, Berneman ZN. Gene-based cancer vaccines: an ex vivo approach. Leukemia 15, 545-558 (2001).
11. Schuler TB, Dieckmann D, Keikavoussi P et al. Mage-3 and influenza-matrix peptide-specific cytotoxic T-cells are inducible in terminal stage HLA-A2.1 + melanoma patients by mature monocyte-derive dendritic cells. J. Immunol. 165, 3492-3496 (2000).
12. Morse MA, Clay TM, Hobeika AC, Mosca PJ, Lyerly HK. Surrogate markers of response to cancer immunotherapy. Expert Opin. Biol. Ther. 1, 153-158 (2001).
13. Rini BI. Technology evaluation: APC-8015, Dendreon. Curr. Opin. Mol. Ther. 4, 76-79 (2002).